Navigation Links
BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
Date:11/8/2012

ersify its existing portfolio. 

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence.  BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Health Solutions.  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
2. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
5. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 UPM Pharmaceuticals, a division of Gregory ... Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has ... first drug approved to treat hypoactive sexual desire disorder ... The tablets will be manufactured at UPM,s ... . Dr. John M. Gregory ...
(Date:3/4/2015)... March 4, 2015 From March 8-11, ... 2015 Distribution Management Conference and Expo in ... HDMA,s largest supply chain education event, attended by ... who keep the pharmaceutical distribution industry moving. Attracting ... and legislative issues important to healthcare distribution and ...
(Date:3/4/2015)... 4, 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer ... and cancer, today announced that James A. Joyce ... corporate overview at the 27th Annual ROTH Conference on ... Laguna Niguel, California . To learn more ... A live webcast of the presentation will ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Aethlon Medical to Present at the 27th Annual ROTH Conference 2
... Biosciences, Inc., a privately held company leading the ... announces one poster presentation and two oral presentations ... meeting on November 14, 2011 during the 9:00 ... presentations highlight results from Regado,s pipeline of antithrombotic ...
... GenturaDx today announced that it will present data from alpha ... Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 ... Of Assay Performance Between Cell Culture And A Rapid Automated ... will address the capability of the GenturaDx IDbox™ System to ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting 2
(Date:3/4/2015)... The federal litigation established for Lipitor ... caused patients to develop Type 2 diabetes continues to ... South Carolina. According to court documents, the proceeding’s next ... at 10:00 a.m. In advance of the Conference, the ... report to the Court by March 19, 2015. (In ...
(Date:3/4/2015)... VIENNA, Austria (PRWEB) March 04, 2015 ... to reduce subjectivity in density assessment and help ... focus of numerous abstracts accepted for presentation at ... 3-8, 2015. Ten abstracts - eight posters ... of Volpara Solutions’ automated breast density and quantitative ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... The print component of “Organic Living” ... Chronicle with a circulation of approximately 173,000 copies and ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... composed of heat-dried microbes that have digested the organic ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... $236.8 billion in 2014 and is estimated to ... CAGR of 4.0% from 2014 to 2019. , ... Gas Market for an analysis of industry trends, ... The global liquefied petroleum gas market is classified ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Specialized one- and two-year Indiana University graduate ... number of health information technology specialists in Indiana ... thanks in part to Recovery Act funding. Two ... learning opportunities. In collaboration with the Regenstrief ...
... HIV could help to develop a vaccine to build antibodies, ... has found. By investigating the action of the human ... to identify that the virus evolves to evade or ,escape, ... Melbourne and one of the senior authors on the paper ...
... pylori , a common stomach bacteria, minimizes the effects of ... of Michigan Medical School scientists. The study published in ... of investigators assembled by senior author John Y. Kao, M.D. ... professor in U-M,s Department of Internal Medicine. The findings indicate ...
... 4, 2011) Autism Speaks, the world,s largest autism ... announced the top awards for "Autism Connects", the international ... by student competitors selected by a juried panel demonstrate ... (ASD) to better connect with the world around them, ...
... 5 (HealthDay News) -- In people with advanced kidney cancer, ... is working, with high blood pressure linked to longer survival, ... of 544 people being treated with the drug sunitinib (Sutent) ... maximum systolic blood pressure reached 140 mmHg or higher survived ...
... New Rochelle, NY, May 5, 2011When children or adolescents ... the disorder, it may impair their ability to manage ... asthma-related anxiety is described in an article in ... published by Mary Ann Liebert, Inc. The article is ...
Cached Medicine News:Health News:IU-Regenstrief programs targeted to alleviate shortage of health IT workforce 2Health News:DNA from common stomach bacteria minimizes effects of colitis, U-M study says 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Blood Pressure May Hint at Kidney Cancer Outcome 2
... CHF test device utilizes ... solid-phase chromatographic immunoassay technology. ... has been dispensed into ... StatusFirst CHF test device ...
... The Vision5L ... high-quality 5- or ... with a signal ... transfer using a ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... test face is used to evaluate both low ... (high, 25% and 12.5%) of LogMAR acuity (20/16 ... as well as the two spatial frequencies of ... widely used for cataract documentation because eye doctors ...
Medicine Products: